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Abstract
Background: Cardiac rehabilitation (CR) is highly effective as secondary prevention for cardiovascular diseases (CVDs).
Uptake of CR remains suboptimal (30% of eligible patients), and long-term adherence to a physically active lifestyle is even
lower. Innovative strategies are needed to counteract this phenomenon.
Objective: The Physical Activity Toward Health (PATHway) system was developed to provide a comprehensive, remotely
monitored, home-based CR program for CVD patients. The PATHway-I study aimed to investigate its feasibility and clinical
efficacy during phase III CR.
Methods: Participants were randomized on a 1:1 basis to the PATHway (PW) intervention group or usual care (UC) control
group in a single-blind, multicenter, randomized controlled pilot trial. Outcomes were assessed at completion of phase II CR and
6-month follow-up. The primary outcome was physical activity (PA; Actigraph GT9X link). Secondary outcomes included
measures of physical fitness, modifiable cardiovascular risk factors, endothelial function, intima-media thickness of the common
carotid artery, and quality of life. System usability and patients’ experiences were evaluated only in PW. A mixed-model analysis
of variance with Bonferroni adjustment was used to analyze between-group effects over time. Missing values were handled by
means of an intention-to-treat analysis. Statistical significance was set at a 2-sided alpha level of .05. Data are reported as mean
(SD).
Results: A convenience sample of 120 CVD patients (mean 61.4 years, SD 13.5 years; 22 women) was included. The PATHway
system was deployed in the homes of 60 participants. System use decreased over time and system usability was average with a
score of 65.7 (SD 19.7; range 5-100). Moderate-to-vigorous intensity PA increased in PW (PW: 127 [SD 58] min to 141 [SD 69]
min, UC: 146 [SD 66] min to 143 [SD 71] min; Pinteraction=.04; effect size of 0.42), while diastolic blood pressure (PW: 79 [SD
11] mmHg to 79 [SD 10] mmHg, UC: 78 [SD 9] mmHg to 83 [SD 10] mmHg; Pinteraction=.004; effect size of −0.49) and
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cardiovascular risk score (PW: 15.9% [SD 10.4%] to 15.5% [SD 10.5%], UC: 14.5 [SD 9.7%] to 15.7% [SD 10.9%]; Pinteraction=.004;
effect size of −0.36) remained constant, but deteriorated in UC.
Conclusions: This pilot study demonstrated the feasibility and acceptability of a technology-enabled, remotely monitored,
home-based CR program. Although clinical effectiveness was demonstrated, several challenges were identified that could influence
the adoption of PATHway.
Trial Registration: ClinicalTrials.gov NCT02717806; https://clinicaltrials.gov/ct2/show/NCT02717806
International Registered Report Identifier (IRRID): RR2-10.1136/bmjopen-2017-016781
(J Med Internet Res 2020;22(2):e14221)  doi: 10.2196/14221
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Introduction
Background
Globally, cardiovascular disease (CVD) is responsible for over
17.3 million deaths annually and accounts for 45% of
noncommunicable deaths [1]. In Europe, over 1.4 million people
die prematurely from cardiovascular-related diseases [2] with
a projected 25% increase in the incidence of CVD by 2030 [3].
Cardiac rehabilitation (CR) is an important component of the
current multidisciplinary approach to the management of patients
with various presentations of CVD [2]. Despite the growing
evidence of the benefits and importance of CR, uptake remains
low with only 30% of eligible patients taking part in an
ambulatory center-based CR program and only 50% of those
maintaining an active lifestyle 6 months after completion of the
program [4].
The reason for low participation rate is multifactorial and
includes time constraints, poor accessibility, transportation
issues, lack of motivation to change behavior, and low
self-efficacy [5]. Home-based programs have proven to be safe
[6] and effective [7] and have enormous potential to widen
access to CR [8]. Furthermore, home-based CR increases
self-efficacy to participate in exercise [9], leading to better
adherence to a physically active lifestyle in comparison with
usual care groups [10]. However, home-based CR interventions
often fail to combine the core components of center-based CR
into one intervention [11]. These core components are identified
as exercise, education, and psychosocial support [12].
Wearable sensors, often worn as a wristband or embedded in a
smartwatch or mobile phone, are now ubiquitous and provide
real-time activity and physiological information that allows
patients to monitor and adjust physical activity (PA) [13] levels
and exercise intensity [14] to meet their rehabilitation goals.
Many CVD patients have internet access, use wearable sensors,
and have a high interest in technology-enabled home-based CR
[15]. In addition, low cost, motion-capturing cameras can
facilitate the execution of appropriate movement patterns in the
home [16,17]. Frederix et al [11] identified telemonitoring,
e-learning, telecoaching, and social networking as the main
focus areas of an effective telerehabilitation intervention, but
only 16% of publications about telerehabilitation combined 2
focus areas and only 5% combined more than 2 focus areas.
Objectives
Physical Activity Toward Health (PATHway) was developed
as an innovative internet-enabled, personalized exercise platform
that incorporates all the core components of CR as well as all
focus areas of telerehabilitation [18-20]. It provides regular
exercise sessions as the basis upon which to provide a
personalized, comprehensive lifestyle intervention program to
enable patients to self-manage their CVD and to lead a healthier
lifestyle in general. The aim of this trial was to assess the
feasibility, acceptance, and short-term clinical effectiveness of
the PATHway system for maintaining PA and physical fitness
of patients with CVD after completion of an ambulatory
center-based CR program.
Methods
Study Design
The PATHway-I trial is a single-blind parallel 2-group
randomized controlled multicenter pilot study (identifier at
ClinicalTrials.gov: NCT02717806) with participant recruitment
from 3 European hospitals (University hospitals Leuven
[Belgium], Mater Misericordiae University hospital in Dublin
[Ireland], and Beaumont University hospital in Dublin [Ireland]),
and measurements were performed between May 2017 and July
2018. The study protocol was approved by the ethics committees
of UZ Leuven/KU Leuven (Belgium; S59023), the Research
Ethics Committees of both Irish hospitals (1/378/1846), and the
ethics committee of Dublin City University (DCU;
REC2016/123), Ireland. The study adhered to the guidelines
set forth by the declaration of Helsinki [21], and participants
provided written informed consent before inclusion. The
PATHway-I trial was conducted and reported in accordance
with the Consolidated Standards of Reporting Trials guidelines
[22]. Our full trial protocol has been published previously [23].
Study Participants
A convenience sample of 120 eligible patients with CVD (aged
40-80 years) was randomized on a 1:1 basis, stratified by
country, to usual care control group (UC) or PATHway
intervention group (PW) during the last 4 weeks of a phase II
outpatient CR program. The randomization schedules were
generated for the different centers using a computerized random
number generator [23].
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The inclusion and exclusion criteria have been reported
previously [23]. To be eligible, patients between 40 and 80 years
had to have documented CVD for which they were enrolled for
the first time in a CR program. Patients needed to be medically
and pharmacologically stable and had to have internet access
and sufficient space at home for deployment of the PATHway
system.
Exclusion criteria were significant illness during the last 6
weeks, known severe ventricular arrhythmia with functional or
prognostic significance, significant myocardial ischemia,
hemodynamic deterioration or exercise-induced arrhythmia at
baseline testing, cardiac disease that limits exercise tolerance
(valve disease with significant hemodynamic consequences,
hypertrophic cardiomyopathy, etc), comorbidity that may
significantly influence 1-year prognosis, functional or mental
disability that may limit exercise, acute or chronic inflammatory
diseases or malignancy, the use of anti-inflammatory drugs or
immune suppression, severe chronic obstructive pulmonary
disease (forced expiratory volume in 1 second <50%), New
York Heart Association class 4, and participation in another
clinical trial.
Study Interventions
A detailed description of the PATHway system and its
development can be found in [18,19,23,24]. During the last 4
weeks of their ambulatory, center-based phase II CR program,
participants allocated to PW enrolled in a weekly familiarization
session alongside their standard CR to get acquainted with the
PATHway intervention [18]. At the same time, the PATHway
system was also installed in the participant’s home, and
participants were encouraged to interact with the system between
familiarization sessions. Figure 1 depicts the flow of participant
enrollment in the study and describes the content of each
familiarization session. After completion of the center-based
CR program, participants completed a cardiopulmonary exercise
test (CPET). The results of the CPET were used to determine
the individual training heart rates, which were then entered into
the PATHway system [25]. Each participant was guided to train
at a heart rate between their first and second ventilatory
thresholds (VT1 and VT2). Heart rate zones were adjusted
according to the results of the 3-month follow-up CPET.
Participants were encouraged to achieve the PA goal of 150 min
of moderate intensity PA per week according to prevailing
guidelines [26]. Different exercise modalities (Exerclass,
Exergame, Active lifestyle activity) were available to the
participant to achieve this goal [18]. In addition, participants in
PW were able to set goals for other lifestyle behaviors, that is,
smoking, diet, alcohol consumption, stress, and medication
adherence. For each of these goals, the participants had the
option to log their behavior and to receive personalized,
automatically generated text messages or emails to support
adherence and progress toward achieving the goal(s).
Participants allocated to UC received verbal advice on how to
best maintain PA and a heart-healthy lifestyle after completion
of the center-based CR program [26]. They did not receive direct
feedback or support with regard to their PA behavior during the
6-month follow-up period. Both groups continued to receive
optimal medical and pharmacological care according to national
and international guidelines [27].
Figure 1. Study flow. CR: cardiac rehabilitation; FAQ: frequently asked questions.
Data Collection and Analysis
Screening procedures and outcome assessments were performed
at local study centers (KU Leuven, Belgium, and DCU, Ireland)
[23]. PA behavior, physical fitness, vascular function, blood
samples, and psychosocial well-being were evaluated 4 weeks
before completion of the center-based phase II CR program and
reassessed 3 months and 6 months after completion of the
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center-based CR program. Although staff involved in the
intervention delivery and troubleshooting of the PATHway
system were clearly not blinded to group allocation, the
investigators collecting the outcome measures were blinded to
group allocation. Patients were instructed not to reveal their
group allocation to these investigators.
Primary Outcome Measures
The primary outcome was the total amount of PA performed
with at least moderate intensity (≥3 metabolic equivalent task
units [METs]; moderate-to-vigorous physical activity [MVPA])
per day, measured using an Actigraph GT9X Link (Actigraph).
Participants were instructed to wear the Actigraph GT9X Link
on the nondominant wrist for 24 h per day during 7 consecutive
days. Data collection was considered valid when at least 4 days
with a recording period of ≥21 h were available [28]. The
Freedson combination algorithm was used to estimate energy
expenditure (EE), whereas the Freedson adult algorithm was
used to estimate MET and cut points for MVPA [28]. Absolute
time spent in sedentary (<0.11 METs), light (0.12-2.99 METs),
moderate (3.00-5.99 METs), and vigorous (≥6.00 METs) activity
[29], as well as the average amount of steps taken per day, were
analyzed.
Secondary Outcome Measures
Health-Related Physical Fitness
Exercise capacity, defined as peak oxygen uptake, was obtained
by means of a CPET on a cycle ergometer (Oxycon Pro Jaeger
[KU Leuven], Marquette 2000, General electric [DCU]). A
10+10 W/min, 20+20 W/min, or 50+25 W/min protocol was
used according to the participants' estimated fitness level to
ensure a CPET duration between the recommended 8 min to
12 min [30]. After reaching maximal volitional fatigue,
participants cycled for another 3 min at 25 W. A 12-lead
electrocardiogram and gas exchange measurements were
recorded continuously, and blood pressure was assessed
automatically every 2 min (Suntech Tango+, SunTech Medical
[KU Leuven], Omron M6-comfort, Omron [DCU]). Peak
oxygen consumption was defined as the highest obtained
average oxygen consumption over 30 seconds during the CPET
[25,31]. The inflection point of the ventilation (VE)/oxygen
uptake (VO2) ratio and VE/exhaled carbon dioxide ratio graphs
were used to determine the VT1 and VT2, respectively [25].
Maximal handgrip strength was measured in both hands using
a hand-held dynamometer (JAMAR Dynamometer, Patterson
Medical [KU Leuven], TAKEI TKK 5101, TAKEI [DCU])
[32,33], and isometric and isokinetic quadriceps strength and
endurance [34] were measured using a Biodex system 3 Pro
(Biodex Medical Systems). A 30-second sit-to-stand test was
performed according to previously published protocols [35].
The best result of each measure was included in the analysis.
Cardiovascular Risk Profile and Vascular Function
Determination of the cardiovascular risk profile included the
assessment of body mass index (BMI; body weight/[body
length]²), fat percentage, waist and hip circumference, blood
pressure and biochemical analysis of blood lipids, plasma
glucose, and plasma insulin.
Fat percentage was measured using a bioelectrical impedance
device (Omron BF306, Omron [KU Leuven], Tanita BF300,
Tanita [DCU]). Waist circumference was measured at the level
of the iliac crest and hip circumference at the level of the great
trochanter. A minimum of 2 measurements was taken and a
third was taken if the initial 2 measurements varied by >1.5 cm
[36]. Office blood pressure was measured 3 times at the left
upper arm with the participant in fasting state and after a 5-min
seated rest (Omron M3, Omron [KU Leuven], Omron
M6-comfort, Omron [DCU]) [37]. Blood sampling was
performed with the participant in a fasting state and included
analysis of plasma glucose, plasma insulin, total cholesterol,
high-density lipoprotein cholesterol, calculated low-density
lipoprotein cholesterol (LDL-C), and triglycerides. Information
relating to current smoking status and the presence/absence of
diabetes mellitus was provided by the participant or obtained
from their health records. These data were used to calculate the
Framingham cardiovascular risk score [38].
High-resolution ultrasonography was used to measure
flow-mediated dilatation (FMD) of the right brachial artery (GE
Ultrasound Vivid 7, GE Healthcare [KU Leuven], Siemens
Acuson, Siemens [DCU]) and carotid intima-media thickness
(cIMT; Philips CX-50, Philips [KU Leuven], Siemens Acuson,
Siemens [DCU]) of the left and right common carotid arteries.
FMD measurements were performed following the protocol of
Corretti et al [39]. cIMT measurements used B-mode ultrasound
image sequences from the longitudinal section of the common
carotid artery, approximately 2 cm below the carotid sinus. For
the analysis of both the FMD and cIMT measurements the
cardiovascular suite software, developed by Quipu (Quipu srl),
was used.
Lifestyle, Health Behaviors, and Quality of Life
During each visit, participants completed a series of Web-based
surveys on a tablet to assess lifestyle, health behaviors, and
quality of life. For an overview of the questionnaires, we refer
to the PATHway-I trial protocol [23]. The current report will
focus on lifestyle behaviors (smoking, diet, medication
adherence, stress, and alcohol consumption) [23], health-related
quality of life (HRQoL) assessed by the short-form 36 (SF-36)
[40], barriers concerning exercise participation [41], exercise
self-efficacy [42], and social support [43] as these are closely
related to PA behavior.
Feasibility and Usability of the Physical Activity Toward
Health System
Adherence to PW was analyzed by generating weekly intervals
of the combined upload frequency of Exerclasses, Exergames,
and Active Lifestyle activities starting from the familiarization
period. Only activities with a total duration between 10 and 500
min were labeled as valid activities and included in the analysis.
A distinction was made between all participants in PW and
those that actively used the PATHway system. Nonusers were
defined as participants randomized to PW without having any
valid uploads for Exerclasses, Exergames, or Active Lifestyle
activities after the familiarization period, all others were
considered active PATHway users.
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All participants in PW received a PA goal at setup of the
program but were free in choosing whether to receive supporting
text messages or emails. On the basis of the scores of lifestyle
behavior questionnaires answered at setup of the program,
participants in PW were provided with the option to set other
lifestyle behavior goals with or without the support of text
messages or email. Usage of the behavior change module of the
PATHway system [23] was assessed by analyzing the selection
of health behavior goals identified by the participant and the
number of total messages delivered in support of these goals.
Participants who opted to not set other behavior change goals
for CVD risk factors or did not want to receive text messages
or emails were considered as nonusers of this feature of the
PATHway system.
The usability and feasibility of the PATHway system was
assessed using the Users Experience Questionnaire (UEQ) [44],
System Usability Scale (SUS) [45], and complemented with
semistructured interviews guided by the Health IT Usability
Evaluation Model [46]. The UEQ provides information relating
to each participant's personal impression of the PATHway
system. It lists 26 opposing words, for example, not
understandable to understandable, separated by a 7-point scale
where −3 indicates the most negative answer, 0 indicates a
neutral answer, and +3 indicates the most positive answer. An
answer below −1 indicates a negative attitude and above +1 a
positive attitude toward the product [47]. The words are related
to 6 scales: perspicuity, efficiency, dependability, attractiveness,
stimulation, and novelty. The first 3 scales indicate the pragmatic
quality of a product whereas the latter 2 scales assess the hedonic
quality. Attractiveness can be seen as a pure valence dimension
[47]. The SUS evaluates the ease of use of the PATHway system
by providing 10 items with a 5-point Likert scale, ranging from
1=strongly disagree to 5=strongly agree. For ease of
interpretation, the SUS is categorized in 6 levels of usability:
the best imaginable, excellent, good, OK, poor, and the worst
imaginable. The semistructured interviews were conducted at
the end of the 6-month follow-up period and consisted of 2
parts. The first part sought the opinion of the participants'
regarding every component of the PATHway system. The
second part consisted of 8 open-ended questions. Full details
regarding this qualitative research part of the study will be
provided separately.
Safety
A serious adverse event (SAE) was defined as all-cause
mortality, hospitalization for CVD, or serious atrial or
ventricular arrhythmia. Adverse events (AE) included
training-related issues such as muscle, tendon, or joint problems
that precluded exercise participation or other diseases that
required an interruption of the exercise intervention. All SAE
or AE were referred to a data safety and monitoring committee
consisting of 4 cardiologists.
Statistical Analysis
SAS University edition, including SAS studio version 3.71
(SAS Institute Inc) was used to analyze the intervention data.
Descriptive continuous data are reported as mean and standard
deviation or as median and interquartile range. Categorical
variables are reported as observed numbers with percentages.
Missing values were handled by means of an intention to treat
analysis, which used the last value carried forward approach.
When baseline data were missing, no imputations were
performed. This approach resulted in an uneven number of
participants in the analyses.
Potential baseline differences between PW and UC and
differences in PA and physical fitness between PATHway users
and nonusers were assessed by independent t test or
Mann-Whitney U test where applicable. Categorical variables
at baseline and (S)AEs were analyzed using the Chi-square
method. Continuous end points were compared between groups
by the use of a mixed-effects analysis of variance (ANOVA)
using SAS PROC MIXED with the study participant modeled
as random effect. The least square mean differences with a
Bonferroni adjustment were used to determine differences within
groups and between groups. Cohen d was used to calculate
effect sizes using the averages of the change within the PW and
UC.
PATHway usage data were analyzed using RStudio version
3.5.1 (R-foundation). Spearman correlation coefficients were
calculated to explore possible links between the PATHway
usage and health outcomes and demographics. A correlation of
0.00 to 0.10 was considered negligible, 0.10 to 0.39 as weak,
0.40 to 0.69 as moderate, 0.70 to 0.89 as strong, and 0.90 to 1.0
as very strong [48].
Statistical significance was set at a 2-sided P value of <.05.
Results
Study Population
A convenience sample of 120 participants out of 218 eligible
patients with CVD was enrolled from May 2017 through
December 2017 (Figure 1) at the 3 different sites (University
Hospitals Leuven [n=60], Beaumont University Hospital Dublin
[n=38], and Mater Misericordiae University Hospital Dublin
[n=22]). A total of 20 participants (20/120, 16.7%) dropped out
(7 PW, 13 UC) during the 6-month period of which 4 were due
to a SAE (Figure 2). Participants who dropped out from the
study did not differ from participants who completed the study.
Baseline characteristics of the participants are summarized in
Table 1. Except for a higher total EE (P=.02) and lower
sedentary time in UC (P=.045), baseline characteristics of both
groups were comparable. This difference in EE remained present
also after correcting for bodyweight. The mean age of
participants was 61.4 years and 82% were men. A total of 83.3%
(100/120) of participants were overweight (BMI>25 kg/m²),
and 26.7% (32/120) were obese (BMI>30 kg/m²). A total of
80.8% (97/120) of participants were referred to CR after a
percutaneous coronary intervention or coronary artery bypass
grafting; and 45.0% (54/120) had a higher degree of education.
Upon completion of the phase II CR program, participants
showed an average physical fitness level of 96% when compared
with their healthy sedentary peers [49]. A comparison between
eligible consenting (n=120) and nonconsenting participants
(n=98) revealed a significant difference in age, with older
participants being less likely to enroll in the study (60.3 [SD
9.2] years vs 64.7 [SD 9.2 years]; P=.001).
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Figure 2. CONSORT (Consolidated Standards of Reporting Trials) flowchart. AE: adverse event; 3mFU: 3-month follow-up; 6mFU: 6-month follow-up;
SAE: serious adverse event.
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Table 1. Baseline physiological characteristics of the total population and per randomized group.
Usual carePATHwayaTotal groupBaseline characteristics
Descriptive characteristics
59.6 (13.2)61.7 (14.5)61.4 (13.5)Age (n=120; years), mean (SD)
49/1149/1198/22Gender (n=120; male/female)
41 (68.3)37 (61.7)78 (65.0)Family history of heart disease (n=119), n (%)
4 (6.70)4 (6.70)8 (6.70)Atrial fibrillation (n=119), n (%)
12 (20.0)6 (10.0)18 (15.0)Self-reported diabetes (n=119), n (%)
Reason for referral
44 (73.3)37 (61.7)81 (67.5)Percutaneous coronary intervention
6 (10.0)10 (16.7)16 (13.3)Coronary artery bypass graft
4 (6.70)2 (3.30)6 (5.0)Valve repair
6 (10.0)11 (18.30)17 (14.2)Otherb
Educational level, n (%)
10 (16.7)6 (10.0)16 (13.3)Primary
26 (43.3)23 (38.3)49 (40.8)Secondary
24 (40.0)30 (50.0)54 (45.0)Higherc
Physical activity (n=111), mean (SD)
1754 (575)1460 (756)1609 (770)Total daily energy expenditure, kcal/day
691 (104)716 (154)700 (120)Sedentary time, min/day
588 (104)575 (115)585 (106)Light physical activity, min/day
141 (114)124 (70.0)127 (101)Moderate-to-vigorous physical activity, min/day
13,225 (4346)12,878 (4410)13,059 (4238)Steps, n/day
Health-related fitness (n=120), mean (SD)
24.4 (9.84)23.2 (8.16)23.3 (8.69)Peak VO2d, mL/min/kg
137 (26.8)142 (24.8)141 (26.3)Peak heart rate, bpm
96.0 (30.8)94.0 (27.5)96.0 (27.5)Wasserman %e, mean (SD)
1.25 (0.15)1.26 (0.14)1.25 (0.14)Peak respiratory exchange ratio
17.0 (4.00)17.0 (2.00)17.0 (3.00)Borg scale
Cardiovascular risk profile, mean (SD)
12.2 (9.70)13.6 (15.3)12.6 (12.6)Risk score (n=119), %
28.2 (5.30)27.4 (3.50)27.9 (4.54)Body mass index (n=120), kg/m²
30.7 (10.6)28.4 (7.41)29.2 (8.64)Percentage fat (n=120), %
0.96 (0.08)0.96 (0.06)0.97 (0.08)Waist/hip ratio (n=120)
5.50 (0.70)5.50 (0.80)5.49 (0.78)Glucose (n=119), mmol/L
56.4 (51.4)50.7 (42.1)54.4 (44.2)Insulin (N=105), pmol/L
3.50 (1.10)3.70 (1.40)3.61 (1.18)Total cholesterol (n=120), mmol/L
1.22 (0.50)1.22 (0.53)1.22 (0.51)High-density lipoprotein cholesterol (n=120), mmol/L
1.62 (0.83)1.78 (1.02)1.75 (0.87)Low-density lipoprotein cholesterol (n=120), mmol/L
0.99 (0.68)1.10 (0.64)1.03 (0.61)Triglycerides (n=120), mmol/L
aPATHway: Physical Activity Toward Health.
bOther includes a combination of coronary artery bypass graft, percutaneous coronary intervention, or valve repair + device implantation.
cCollege or university.
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dVO2: oxygen uptake.
eWasserman %: percent predicted oxygen uptake.
Primary Outcome: Physical Activity
Average daily MVPA increased significantly in PW between
baseline and 6 months (P=.01). There was no change in the
average daily minutes of MVPA in UC (P=.60; Figure 3). This
resulted in a significant interaction effect between groups over
time (Pinteraction=.04). A significant decrease in low-intensity
PA in UC over time was present (P=.04), which resulted in a
trend toward a significant interaction effect (Pinteraction=.11).
Table 2 provides point measures on all PA outcomes.
Figure 3. Evolution of moderate-to-vigorous physical activity per day over time in minutes. 6mFU: 6-month follow-up.
Table 2. Intervention effects on daily physical activity behavior (N=111).
P valueEffect sizeUsual care, mean (SD)PATHwaya, mean (SD)Intervention effects on daily physical activity
6 monthsBaseline6 monthsBaseline
.360.141789 (714)1805 (650)1560 (563)1529 (538)Total daily energy expenditure, kcal/day
.11−0.32675 (98.0)649 (89.0)698 (130)659 (137)Sedentary time, min/day
.110.33576 (86.0)596 (75.0)579 (74)576 (75)Light physical activity time, min/day
.040.42143 (70.6)146 (65.9)141 (69.1)127 (57.9)Moderate-to-vigorous physical activity, min/day
.200.2812,940 (2821)13,323 (3200)12,612 (3308)12,563 (2870)Steps, n/day
aPATHway: Physical Activity Toward Health.
Secondary Outcomes
Health-Related Physical Fitness
Health-related physical fitness outcome measures at baseline
and 6 months are summarized in Table 3. During the follow-up
period, there were no significant differences between groups
regarding peak VO2 (Pinteraction=.64), predicted peak VO2
(Pinteraction=.79), and VO2 at VT1 (Pinteraction=.91). Significant
time-effects were found for isometric (Ptime<.001) and isokinetic
(Ptime=.046) quadriceps strength as well as the 30-second
sit-to-stand test (Ptime<.001), without leading to significant
interaction effects.
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Table 3. Intervention effects on health-related physical fitness.
P valueEffect sizeUsual care, mean (SD)PATHwaya, mean (SD)Intervention effects on health-related physical fitness
6 monthsBaseline6 monthsBaseline
Cardiopulmonary exercise testing (n=120)
.640.0924.5 (6.50)24.5 (7.10)24.1 (5.82)23.8 (5.47)Peak VO2b, mL/min/kg
.790.0599.3 (20.4)98.8 (21.8)95.4 (18.5)94.0 (21.3)Wasserman %c, %
.55−0.111.25 (0.10)1.24 (0.09)1.27 (0.10)1.27 (0.11)Peak respiratory exchange rate
.91−0.021155 (339)1180 (376)1076 (284)1106 (314)VO2 at first threshold, mL/min
.890.0317 (2)17 (2)16 (2)16 (2)Borg score
Muscle strength
.83−0.0439.5 (11.4)39.4 (11.0)40.1 (11.4)40.1 (11.0)Handgrip strength dominant side (n=118), kg
.570.1136.4 (10.4)36.6 (10.1)38.7 (10.0)38.3 (9.90)Handgrip strength nondominant side (n=118), kg
.38−0.16158 (48.2)149 (48.1)154 (47.1)150 (45.7)Isometric quadriceps strength (n=117), Nm
.660.092124 (677)2082 (701)2150 (678)2085 (725)Isokinetic upper leg strength (n=117), J
.94−0.0122.0 (7.00)18.0 (7.00)22.0 (6.00)19.0 (4.00)30s sit-to-stand test (n=118), n
aPATHway: Physical Activity Toward Health.
bVO2: oxygen uptake.
cWasserman %: percent predicted oxygen uptake according to Hansen et al [49].
Cardiovascular Risk Profile and Vascular Function
Participants in PW maintained a stable CV risk score, whereas
participants in UC increased their risk during the 6-month
follow-up period (Pinteraction=.03). The same applies for diastolic
blood pressure (Pinteraction=.004) and the trends that could be
seen in waist-hip ratio (Pinteraction=.07), LDL-C (Pinteraction=.12),
and systolic blood pressure (Pinteraction=.10; Table 4). There was
no significant difference in FMD or cIMT between PW and UC
at any time point. There was a significant time main effect for
left cIMT (P=.03), indicating a significant decrease between
baseline and 6 months.
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Table 4. Intervention effects on cardiovascular risk profile and vascular function.
P valueEffect sizeUsual care, mean (SD)PATHwaya, mean (SD)Intervention effects on cardiovascular risk profile and
vascular function
6 monthsBaseline6 monthsBaseline
Cardiovascular risk profile
.03−0.3615.7 (10.9)14.5 (9.70)15.5 (10.5)15.9 (10.4)Risk score (n=115), %
.23−0.1929.2 (4.30)28.9 (4.20)27.5 (3.60)27.4 (3.60)Body mass index (n=120), kg/m²
.85−0.0331.4 (7.10)30.8 (7.30)29.2 (5.80)28.7 (5.80)Body fatb (n=120), %
.070.080.96 (0.08)0.96 (0.08)0.94 (0.08)0.95 (0.09)Waist/hip ratio (n=120)
.48−0.105.91 (1.88)5.70 (1.66)5.83 (1.26)5.72 (1.24)Glucose (n=119), mmol/L
.810.0364.3 (34.9)57.1 (29.7)71.0 (52.3)61.3 (35.3)Insulin (n=104), pmol/L
.99−0.022.46 (1.61)2.07 (1.11)2.73 (2.42)2.30 (1.61)HOMA1-IRc (n=104)
.15−0.253.84 (1.08)3.66 (0.95)3.81 (1.01)3.82 (0.97)Total cholesterol (n=120), mmol/L
.29−0.181.34 (0.47)1.30 (0.41)1.28 (0.33)1.29 (0.36)High-density lipoprotein cholesterol (n=120),
mmol/L
.12−0.262.01 (0.87)1.84 (0.78)1.95 (0.80)1.96 (0.79)Low-density lipoprotein cholesterol (n=120),
mmol/L
.31−0.351.20 (0.56)1.11 (0.57)1.25 (0.65)1.25 (0.66)Triglycerides (n=120), mmol/L
.10−0.27131 (20.0)125 (13.0)127 (16.0)126 (17.0)Systolic blood pressure (n=120), mmHg
.004−0.4983.0 (10.0)78.0 (9.00)79.0 (10.0)79.0 (11.0)Diastolic blood pressure (n=120), mmHg
Vascular function
.30−0.174.33 (0.61)4.26 (0.65)4.13 (0.62)4.17 (0.68)Brachial artery diameter in rest (n=109), mm
.92−0.014.63 (0.66)4.60 (0.75)4.49 (0.66)4.49 (0.73)Brachial artery diameter post occlusion (n=109),
mm
.200.286.94 (5.20)8.00 (6.40)8.90 (4.90)8.10 (7.40)Flow-mediated dilatation (n=109), %
.830.140.68 (0.15)0.71 (0.16)0.68 (0.21)0.72 (0.15)IMTd left (n=114), mm
.660.140.65 (0.17)0.65 (0.16)0.67 (0.20)0.68 (0.17)IMT right (n=116), mm
aPATHway: Physical Activity Toward Health.
bFat%: fat percentage.
cHOMA1-IR: Homeostatic Model Assessment of Insulin Resistance.
dIMT: intima media thickness.
Lifestyle, Health Behaviors, and Quality of Life
Table 5 provides a detailed overview of the questionnaire scores
assessing lifestyle, health behaviors, and quality of life. Overall,
a small decrease in exercise self-efficacy was observed over the
6-month period (Ptime=.03), without differences between groups
(Pinteraction=.24). Except for a trend toward a subtle decrease in
alcohol consumption in PW (Pinteraction=.08), lifestyle behaviors
including medication adherence, diet, and stress remained stable
over time in both groups. Measures of mental well-being, as
assessed by the Warwick-Edinburgh Mental Well-Being Scale,
were improved after the intervention period (Ptime=.03), without
any interaction effect between groups. HRQoL as assessed by
means of the SF-36 did not change over the 6-month period.
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Table 5. Intervention effects on lifestyle, health behaviors, and quality-of-life outcomes.
P valueEffect sizeUsual care, mean (SD)PATHwaya, mean (SD)
Intervention effects on lifestyle, health behaviors, and quality-
of-life
6 monthsBaseline6 monthsBaseline
Mediators of change in physical activity (N=120)
.480.1420.7 (3.52)21.1 (2.67)20.5 (3.06)21.3 (2.57)Exercise intentions
.190.1428.1 (6.73)28.4 (5.83)28.3 (6.98)27.3 (6.30)Exercise planning
.830.0468.9 (22.8)70.5 (21.5)67.3 (22.5)68.1 (23.1)Exercise barriers (barriers self-efficacy scale)
.24−0.2379.7 (20.0)81.1 (19.1)78.3 (18.3)83.3 (17.7)Exercise self-efficacy (exercise self-efficacy scale)
.94−0.0227.0 (3.61)27.0 (3.36)27.2 (3.95)27.3 (3.56)Social support (ENRICHDb social support instrument)
Lifestyle assessment (N=120)
.25−0.206.20 (2.15)5.95 (2.08)6.35 (1.93)6.47 (2.12)Diet (Mediterranean diet adherence screener)
.30−0.096.78 (0.87)6.70 (1.01)6.70 (0.89)6.78 (0.98)Medication adherence (Morisky medication adherence
scale)
.86−0.01111.6 (6.98)11.9 (6.35)10.9 (7.84)11.4 (7.22)Stress (perceived stress scale)
.08−0.383.08 (2.29)2.90 (2.01)3.10 (2.43)3.23 (2.53)Alcohol consumption (alcohol use disorders identification
test)
Quality of life (N=120)
.60−0.1176.1 (18.3)75.0 (16.2)77.0 (18.2)76.9 (16.5)Health-related quality of life (short form 36)
.86−0.283.27 (4.21)3.17 (3.34)3.43 (4.79)3.25 (3.76)Perceived health (perceived health questionnaire)
.060.0657.0 (9.65)55.0 (8.50)57.0 (10.1)56.9 (9.42)Mental well-being (Warwick-Edinburgh mental well-being
scale)
aPATHway: Physical Activity Toward Health.
bENRICHD: Enhancing Recovery in Coronary Heart Disease.
Exploratory Analysis of Physical Activity Toward Health
Use and Health Outcomes
PATHway use was defined as the total amount of time spent
using the Active lifestyle, Exerclass, or Exergame option. If a
spearman correlation between PATHway use and age, PA, and
physical fitness outcomes was significant, then the magnitude
of the correlation is depicted in Figure 4 [49]. Only the change
in peak heart rate, change in peak systolic blood pressure, and
change in peak load during CPET were significantly correlated
with PATHway use, but the correlations were weak with values
of −0.30, −0.31, and −0.33, respectively. Furthermore, no
significant differences were present concerning PA and physical
fitness outcomes between users and nonusers of the PATHway
system.
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Figure 4. Exploratory analysis of significant correlation coefficients between Physical Activity Toward Health use and demographics, physical activity,
and physical fitness. diff: difference; EE: energy expenditure; HRVAT: heart rate at the first ventilatory threshold; MVPA: moderate-to-vigorous physical
activity; pHR: peak heart rate; pLoad: peak load; pRER: peak respiratory exchange ratio; pSBP: peak systolic blood pressure; percentVO2VAT: percent
oxygen uptake at first ventilatory threshold; predicted_VO2: predicted oxygen uptake according to Hansen; pVE: peak ventilation; pVO2: peak oxygen
consumption; VO2VAT: oxygen uptake at first ventilatory threshold; WVAT: load at first ventilatory threshold; Sed: sedentary time.
Feasibility and Usability of the Physical Activity
Toward Health System
Use of the Physical Activity Toward Health System
The most frequently used PA component was Active lifestyle
recorded by means of the Microsoft band 2 (median number of
sessions during 6 months: 27, range 2.5-89.5), followed by
Exerclasses (median number of sessions during 6 months: 14.5,
range: 3-35.8), Exergames (median number of sessions during
6 months: 1, range: 0-3), and manually inserted yet not
objectively measured activities (median: 0 range: 0-4). A total
of 34 participants (34/60, 57%) set at least one extra goal for
CVD risk factor modification using the behavior change module.
From the selected goals, 54% related to healthy eating, followed
by stress management (17%), alcohol moderation (13%), and
medication adherence (12%). PATHway usage decreased over
time with a significant lower number of performed exercise
sessions using the PATHway system starting at month 4
compared with month 1 (P<.001). Figure 5 depicts the decrease
in PATHway use over time.
Figure 5. Average amount of exercise sessions per week using the Physical Activity Toward Health system.
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Feasibility and Usability
In total, 46 participants (46/60, 77%) in PW completed the UEQ
and SUS. Of which, 4 out of 6 scales of the UEQ, including the
2 scales assessing the hedonic quality of a product, had an above
average mean score of more than 1 (such as attractiveness,
perspicuity, stimulation, and novelty). The 2 other scales
(dependability and efficiency), indicating pragmatic quality of
a product, scored below average with mean scores of less than
1.
The mean score (SD) of the SUS was 65.5 (19.7), and 5
participants indicated the usability of the PATHway system as
the best imaginable, 13 participants as excellent, 18 participants
as good, 4 participants as OK, 5 participants as poor, and 1
participant as the worst imaginable.
Safety
The rates of AEs were similar in PW and UC (Figure 6). No
AEs related to exercise occurred.
Figure 6. Overview of adverse events during the trial. AE: adverse events; CABG: coronary artery bypass grafting; HF: heart failure; PCI: percutaneous
coronary intervention; SAE: serious adverse events.
Discussion
Principal Findings
This study evaluated the feasibility, acceptability, and clinical
effectiveness on MVPA and cardiovascular risk profile of a
comprehensive technology-enabled, home-based CR system.
We found above average scores on 4 out of 6 scales of user
experience, 78% of participants indicated at least good usability
of the system, and there were no usage-related AEs. Moreover,
the PW intervention seems effective for supporting MVPA in
daily life after graduating from hospital-based CR.
It was hypothesized that the PATHway platform would aid in
maintaining the adherence to a heart healthy active lifestyle
following completion of a supervised phase II CR program.
MVPA increased in PW by 11%, whereas the levels of MVPA
decreased by 2% in UC, resulting in a significant
interaction-effect between groups over time and an effect size
of 0.42. Previous studies have also reported a better short-term
maintenance of PA following telerehabilitation [50,51].
Nevertheless, as absolute MVPA levels at 6-month follow-up
are almost equal for both groups in our study, we need to
acknowledge that some effects of regression toward the mean
might be present, and these positive results need confirmation
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from larger trials. Our effect on MVPA did not translate into a
positive effect on exercise capacity, the parameter most strongly
related to morbidity and mortality, indicating that this effect
might not be large enough to be clinically meaningful, at least
not in this short timeframe of 6 months. Interestingly, daily
MVPA at both baseline and 6 months were more than 3 times
greater than the values reported by Prince et al [52] regarding
CR graduates (63.6 [SD 9.6] years, 75% male, peak VO2 after
CR of 25.2 [SD 6.6] mL/min/kg) wearing Actigraph GT3X
accelerometer at the hip during waking hours. Participants in
this study wore the Actigraph GT9X Link on the nondominant
wrist for 24 h/day. Research shows that more accurate MVPA
results are obtained when the device is worn on the hip
compared with the wrist, which might in part be due to the lack
of validated accelerometry algorithms for wrist-worn devices
[28]. As such, daily MVPA found in this study may have been
overestimated. In line with this thought, high MVPA values
were also found in a sample of obese individuals wearing the
Actigraph GT3X at the wrist [53].
For physical fitness as well as most other outcome measures,
we could only document trivial (<.2) effect sizes. Because
participants were on average quite fit (96% of predicted
sedentary values) at completion of phase II CR, no further
improvement in physical fitness was to be expected. Contrary
to our hypothesis, whereby we expected a larger decrease in
physical fitness in UC, both groups were able to maintain their
level of physical fitness. The lack of differences between both
groups could be attributable to the small study groups, the
motivation to remain fit because of the scheduled follow-up
testing as well as the relatively short time period of the trial.
On the other hand, the hypothesized deterioration in UC did
occur in relation to the cardiovascular risk score and diastolic
blood pressure. Both increased significantly in UC (P=.003 and
P<.001, respectively), while remaining stable in PW and this
resulted in significant differences between groups over time. A
potential explanation for this finding might be the use of the
behavior change module in PW. This module is based on 22
behavior change techniques [18] that can help increase
compliance to healthy behaviors and thus have an influence on
total cardiovascular risk score [54]. However, our data cannot
support this assumption, as the choice to set healthy living goals
was not statistically translated into better outcome scores.
Participants’ usage of the PATHway system decreased over
time, with the decline starting in the 4th month. Weaknesses of
the chosen heart rate tracker, as well as the rather limited suite
of exercises/games incorporated into the PATHway system may
have been a contributing factor to the decline in usage. Studies
examining the use of PA trackers to maintain levels of PA also
indicate a gradual decrease in usage, with a sustainability of the
use of this technology ranging from 129 days [55] to 5 to 7
months [56]. Factors that increase sustained technology use
include ease of use, absence of technology failure, high
educational background, younger age, and female gender [55].
It is important to note that use of technology is not necessarily
equal to adherence to a desired health behavior. We reported
the participants’ engagement with the PATHway system by
means of usage data, but engagement is a complex construct
and should likely be measured by a combination of methods,
which are also context dependent [57].
To maximize engagement, usability, and adherence, the
PATHway system was developed in consultation with the target
users [18]. The majority of the study participants found
PATHway easy to use. However, software problems were
identified when the system was first deployed in the participant’s
home. The software issues were resolved with 2 major updates
during the study, resulting in a more mature system emerging
during the later phase of the trial. It is likely that persistent
technology-related issues may have frustrated the study
participants and have had a negative impact on the use of the
system [58]. In line with this thought, the debrief interviews
that will be described in detail separately, documented the need
for future improvements and expansion to increase the longevity
of this mode of CR delivery. In agreement with Hermsen et al
[55], we also found that younger CR patients were more likely
than older patients to participate in the study. Although almost
90% of participants in PW had completed secondary education
and 50% had a higher education degree, we did not find a
significant relation between PATHway usage and educational
level.
The documented decrease in exercise self-efficacy may also
help explain a decrease in use of technology [59]. It is possible
that baseline self-efficacy scores are too optimistic because at
the time of baseline measurements, the study participants were
still participating in supervised, very structured, and
well-organized phase II CR. When the participants graduated
from CR and needed to implement an exercise routine in their
home environment, they may have come to a better
understanding of the requirements and challenges of exercise
self-efficacy, resulting in lower scores. On the other hand, one
might also argue that reaching daily PA goals could also give
the participant the feeling he/she no longer needs the PATHway
technology to remain physically active [56]. Indeed, the decrease
in PATHway usage did not result in a decrease in the daily
MVPA and physical fitness.
The study participants in this project were predominantly men,
as is in line with how men and women are distributed in
ambulatory CR in todays practice in the hospitals participating
in this trial. One reason for this might be that the ambulatory
CR program in its current format is more appealing to men,
compared with women. Furthermore, there is some evidence
that women are also significantly less likely to be referred for
CR programs following revascularization compared with men
[60]. Advances in cardiovascular research is documenting
sex-specific differences with regard to diagnosis and treatment
of heart disease. To be able to draw conclusions that apply to
both sexes, it would have been better to have an equal
distribution of women and men in this study. For now, our
results should be interpreted with more caution when applied
to women with heart disease.
Limitations
This study was a pilot study including 120 participants. Post
hoc power analysis for the outcome measure of MVPA (primary
outcome) revealed that our sample size was more than sufficient
(100% power). Also, for the cardiovascular risk score, our
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sample size was sufficient. The number of participants would
need to be (much) greater for detecting differences in most of
the secondary outcome measures. For example, based on
obtained effect size, a sample size of 170 patients in total would
have been needed to achieve 80% power at an alpha-error
probability of .05 for the outcome measure of peak VO2.
Furthermore, it is worth mentioning that a longer follow-up
duration might have resulted in a larger difference between
intervention and control group because regression to a more
sedentary lifestyle might not show straight away in
cardiovascular risk factors and physical fitness. Therefore, a
longer follow-up should be envisaged in future research with
better power.
Because participants could only be enrolled in the study if they
completed phase II CR, selection bias toward a highly motivated
and physical active study group might have existed. The
follow-up period of 6 months can be considered short as the
aim of home-based CR is to induce changes in the remaining
life of the participant.
Despite extensive testing of the PATHway platform during
development, technical errors occurred during the early part of
the trial when a significant number of participants started using
the PATHway platform at the same time. Complex technology
should be stress-tested on a larger scale before implementation
in a trial of this size. This seems to be of particular concern for
systems that incorporate multiple components, hosted at
different sites with use of the internet for communication.
As there are no adequately validated algorithms for the
wrist-worn Actigraph GT9X Link, the choice to wear it at the
nondominant wrist resulted in high absolute PA values and
absolute values might thus not be accurate [28]. However, since
we opted for a 24 h/day protocol and the watch had also to be
worn during the night, wearing the device at the wrist would
most likely result in better wear-time compliance [28], which
is why this device was chosen. As both PW and UC received
the same wearing instructions and the same set-up protocol was
applied at baseline and 6-month follow-up, we believe our
results concerning detected differences in PA are reliable.
We observed a significant age difference between consenting
and nonconsenting participants, suggesting that caution is
warranted when extrapolating the results of acceptability and
feasibility of a technological intervention to all CR participants.
Conclusions
Usage of the PATHway platform for home-based CR following
completion of ambulatory CR was demonstrated to be feasible
and acceptable for the participants and allowed for safe training
sessions. The PATHway platform showed preliminary
effectiveness for improving adherence to a physically active
lifestyle. The PATHway platform was well received by the
users, yet several challenges were identified that should be
tackled to result in a more mature technological solution and to
increase long-term adoption of a heart-healthy physically active
lifestyle. The results of this work can be used as a basis for the
design of future RCTs and for sample size calculations to reach
statistical power. Future long-term and well-powered studies
should focus on implementing those features of the PATHway
system that were used most frequently and deemed most useful
according to the users. Moreover, the variety of the offered
exercises and exercise modes should be increased to improve
adherence on the longer term.
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